Moderna (MRNA) Payables (2017 - 2025)
Historic Payables for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $267.0 million.
- Moderna's Payables fell 2841.82% to $267.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $267.0 million, marking a year-over-year decrease of 2841.82%. This contributed to the annual value of $405.0 million for FY2024, which is 2211.54% down from last year.
- According to the latest figures from Q3 2025, Moderna's Payables is $267.0 million, which was down 2841.82% from $175.0 million recorded in Q2 2025.
- In the past 5 years, Moderna's Payables registered a high of $520.0 million during Q4 2023, and its lowest value of $8.0 million during Q1 2021.
- In the last 5 years, Moderna's Payables had a median value of $279.0 million in 2024 and averaged $278.5 million.
- As far as peak fluctuations go, Moderna's Payables skyrocketed by 238750.0% in 2022, and later tumbled by 5295.63% in 2024.
- Quarter analysis of 5 years shows Moderna's Payables stood at $302.0 million in 2021, then skyrocketed by 61.26% to $487.0 million in 2022, then rose by 6.78% to $520.0 million in 2023, then fell by 22.12% to $405.0 million in 2024, then plummeted by 34.07% to $267.0 million in 2025.
- Its Payables was $267.0 million in Q3 2025, compared to $175.0 million in Q2 2025 and $226.0 million in Q1 2025.